Abstract
Induction chemotherapy for squamous cell carcinoma of the head and neck has long been known to be highly active with tumor responses observed in a high percentage of patients. More recent studies have added taxane to traditional platin and infusional fluorouracil regimens. Docetaxel, cisplatin and 5-fluorouracil (TPF) is presently studied in prospective controlled trials to better define the efficacy and potential toxicity of sequential treatment with TPF followed by concomitant chemoradiotherapy. We await the results of these trials before we accept induction chemotherapy as a standard treatment and to best identify the subgroups of patients who may be most likely to benefit from the approach.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.